Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia

Masashi Ikeda, Yoshio Yamanouchi, Yoko Kinoshita, Tsuyoshi Kitajima, Reiji Yoshimura, Shuji Hashimoto, Michael C. O'Donovan, Jun Nakamura, Norio Ozaki, Nakao Iwata

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Aims: Abnormalities in dopaminergic and serotonergic transmission systems are thought to be involved in the pathophysiology of schizophrenia and the mechanisms underlying the therapeutic effects of antipsychotics. We conducted a pharmacogenetic study to evaluate whether variants in dopamine-related genes (DRD1-DRD5, AKT1 and GSK3β) and serotonin receptor genes (HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6 and HTR7) can be used to predict the efficacy of risperidone treatment for schizophrenia. Materials & methods: A total of 120 first-episode neuroleptic-naive schizophrenia patients were treated with risperidone monotherapy for 8 weeks and clinical symptoms were evaluated by the Positive and Negative Syndrome Scale. Results: Among the 30 variants that we examined, two SNPs in DRD2 (-241A>G [rs1799978] and TaqIA, [rs1800497]) and two SNPs in AKT1 (AKT1-SNP1 [rs3803300] and AKT1-SNP5 [rs2494732]) were significant predictors of treatment response to risperidone. Conclusion: These data suggest that the SNPs in DRD2 and AKT1 may intluence the treatment response to risperidone in schizophrenia patients.

Original languageEnglish
Pages (from-to)1437-1443
Number of pages7
JournalPharmacogenomics
Volume9
Issue number10
DOIs
Publication statusPublished - 13-11-2008

Fingerprint

Risperidone
Dopamine
Serotonin
Schizophrenia
Single Nucleotide Polymorphism
Antipsychotic Agents
Genes
Serotonin Receptors
Therapeutic Uses
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Ikeda, Masashi ; Yamanouchi, Yoshio ; Kinoshita, Yoko ; Kitajima, Tsuyoshi ; Yoshimura, Reiji ; Hashimoto, Shuji ; O'Donovan, Michael C. ; Nakamura, Jun ; Ozaki, Norio ; Iwata, Nakao. / Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. In: Pharmacogenomics. 2008 ; Vol. 9, No. 10. pp. 1437-1443.
@article{43e17161e8a041f1be244e400111737a,
title = "Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia",
abstract = "Aims: Abnormalities in dopaminergic and serotonergic transmission systems are thought to be involved in the pathophysiology of schizophrenia and the mechanisms underlying the therapeutic effects of antipsychotics. We conducted a pharmacogenetic study to evaluate whether variants in dopamine-related genes (DRD1-DRD5, AKT1 and GSK3β) and serotonin receptor genes (HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6 and HTR7) can be used to predict the efficacy of risperidone treatment for schizophrenia. Materials & methods: A total of 120 first-episode neuroleptic-naive schizophrenia patients were treated with risperidone monotherapy for 8 weeks and clinical symptoms were evaluated by the Positive and Negative Syndrome Scale. Results: Among the 30 variants that we examined, two SNPs in DRD2 (-241A>G [rs1799978] and TaqIA, [rs1800497]) and two SNPs in AKT1 (AKT1-SNP1 [rs3803300] and AKT1-SNP5 [rs2494732]) were significant predictors of treatment response to risperidone. Conclusion: These data suggest that the SNPs in DRD2 and AKT1 may intluence the treatment response to risperidone in schizophrenia patients.",
author = "Masashi Ikeda and Yoshio Yamanouchi and Yoko Kinoshita and Tsuyoshi Kitajima and Reiji Yoshimura and Shuji Hashimoto and O'Donovan, {Michael C.} and Jun Nakamura and Norio Ozaki and Nakao Iwata",
year = "2008",
month = "11",
day = "13",
doi = "10.2217/14622416.9.10.1437",
language = "English",
volume = "9",
pages = "1437--1443",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "10",

}

Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. / Ikeda, Masashi; Yamanouchi, Yoshio; Kinoshita, Yoko; Kitajima, Tsuyoshi; Yoshimura, Reiji; Hashimoto, Shuji; O'Donovan, Michael C.; Nakamura, Jun; Ozaki, Norio; Iwata, Nakao.

In: Pharmacogenomics, Vol. 9, No. 10, 13.11.2008, p. 1437-1443.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia

AU - Ikeda, Masashi

AU - Yamanouchi, Yoshio

AU - Kinoshita, Yoko

AU - Kitajima, Tsuyoshi

AU - Yoshimura, Reiji

AU - Hashimoto, Shuji

AU - O'Donovan, Michael C.

AU - Nakamura, Jun

AU - Ozaki, Norio

AU - Iwata, Nakao

PY - 2008/11/13

Y1 - 2008/11/13

N2 - Aims: Abnormalities in dopaminergic and serotonergic transmission systems are thought to be involved in the pathophysiology of schizophrenia and the mechanisms underlying the therapeutic effects of antipsychotics. We conducted a pharmacogenetic study to evaluate whether variants in dopamine-related genes (DRD1-DRD5, AKT1 and GSK3β) and serotonin receptor genes (HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6 and HTR7) can be used to predict the efficacy of risperidone treatment for schizophrenia. Materials & methods: A total of 120 first-episode neuroleptic-naive schizophrenia patients were treated with risperidone monotherapy for 8 weeks and clinical symptoms were evaluated by the Positive and Negative Syndrome Scale. Results: Among the 30 variants that we examined, two SNPs in DRD2 (-241A>G [rs1799978] and TaqIA, [rs1800497]) and two SNPs in AKT1 (AKT1-SNP1 [rs3803300] and AKT1-SNP5 [rs2494732]) were significant predictors of treatment response to risperidone. Conclusion: These data suggest that the SNPs in DRD2 and AKT1 may intluence the treatment response to risperidone in schizophrenia patients.

AB - Aims: Abnormalities in dopaminergic and serotonergic transmission systems are thought to be involved in the pathophysiology of schizophrenia and the mechanisms underlying the therapeutic effects of antipsychotics. We conducted a pharmacogenetic study to evaluate whether variants in dopamine-related genes (DRD1-DRD5, AKT1 and GSK3β) and serotonin receptor genes (HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6 and HTR7) can be used to predict the efficacy of risperidone treatment for schizophrenia. Materials & methods: A total of 120 first-episode neuroleptic-naive schizophrenia patients were treated with risperidone monotherapy for 8 weeks and clinical symptoms were evaluated by the Positive and Negative Syndrome Scale. Results: Among the 30 variants that we examined, two SNPs in DRD2 (-241A>G [rs1799978] and TaqIA, [rs1800497]) and two SNPs in AKT1 (AKT1-SNP1 [rs3803300] and AKT1-SNP5 [rs2494732]) were significant predictors of treatment response to risperidone. Conclusion: These data suggest that the SNPs in DRD2 and AKT1 may intluence the treatment response to risperidone in schizophrenia patients.

UR - http://www.scopus.com/inward/record.url?scp=55649099694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649099694&partnerID=8YFLogxK

U2 - 10.2217/14622416.9.10.1437

DO - 10.2217/14622416.9.10.1437

M3 - Article

C2 - 18855532

AN - SCOPUS:55649099694

VL - 9

SP - 1437

EP - 1443

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 10

ER -